Posted by Michael Wonder on 12 Jun 2025
Sumitomo Pharma America announces that nuvisertib (TP-3654) has received FDA fast track designation for the treatment of myelofibrosis
12 June 2025 - Nuvisertib (TP-3654), an investigational highly selective oral PIM1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis.
Sumitomo Pharma America today announced that the US FDA granted fast track designation to nuvisertib (TP-3654) for the treatment of patients with intermediate or high-risk myelofibrosis.
